<DOC>
	<DOCNO>NCT02779634</DOCNO>
	<brief_summary>There study specifically examine effect coenzyme Q ( CoQ ) treatment echocardiographic index diastolic function elderly patient heart failure preserve ejection fraction ( HFPEF ) . In previous study echocardiographic parameter study ejection fraction ( EF ) chamber size . The objective propose current study examine effect 16 week ubiquinol therapy diastolic function assess echocardiography patient age 50 clinical diagnosis HFPEF . Ubiquinol ( Kaneka Pharma ) , reduce form CoQ utilize study show superior bioavailability compare oxidized CoQ .</brief_summary>
	<brief_title>Ubiquinol Treatment Patients With Heart Failure Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Typical sign symptom congestive heart failure ( CHF ) ( New York Association Class 24 ) . Normal ejection fraction echocardiography ( EF â‰¥50 % ) . Evidence diastolic dysfunction noninvasive imaging ( E : e ' &gt; 15 e : e ' &gt; 8 measure diastolic dysfunction e/a &lt; 0.5 elevated deceleration time leave atrial volume index &gt; 40 cc/m2 presence elevate leave ventricular mass index elevate pulmonary pressure ) . Stable medical therapy 4 week prior randomization Chronic atrial fibrillation . Acute coronary syndrome coronary revascularization within 60 day . Clinically significant valvular disease . Known infiltrative cardiomyopathy ( e.g . amyloidosis ) , hypertrophic cardiomyopathy chronic pericardial disease . Inability/refusal provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>